Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are novel therapeutic agents for type 2 diabetes mellitus by inhibiting the glucose reabsorption in renal proximal tubules. Here, SLC5A2 is linked to type 2 diabetes mellitus.